Capivasertib China PK Study

Exclusion Criteria

• •Histologically or, where appropriate, cytologically-confirmed malignant solid tumour refractory or resistant to standard therapy and for which no suitable effective standard therapy exists
• •Participants must have a life expectancy of ≥12 weeks
• •Participants must be eligible for paclitaxel treatment as per local investigator assessment
• •ECOG performance status 0-1
• •Participants must be on a stable concomitant medication regimen, defined as no changes in medication or in dose within 2 weeks prior to start of capivasertib dosing, except for bisphosphonates, denosumab and corticosteroids, which should be stable for at least 4 weeks prior to start of capivasertib dosing
• •Radiotherapy with a wide field of radiation within 4 weeks before the first dose of study treatment
• •Other malignancies within 5 years prior to treatment initiation (except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer)
• •Participants with any ongoing toxicities (\>CTCAE grade 2), with the exception of alopecia, caused by previous cancer therapy
• •Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
• •Any of the following cardiac criteria at screening:
• +14 more criteria